Victoria Lawson, MD
Neuromuscular Medicine · Lebanon, NHNPI 1124118732
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (58.2%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Sanofi accounts for 84.0% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2023 at $41,050 and has fallen 93.7% since, to $2,572 in 2024.
Across 23 payments — averaging $2252.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$44K
- Chiesi USA, Inc.$6K
- AstraZeneca$2K
- Biogen$117
- Alnylam Pharmaceuticals Inc.$73
Across 1 payment — averaging $22,969 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vertex$23K
What the payments were for
- Consulting fees$30,17258%
- Travel & lodging$21,24441%
- Food & beverage$2861%
- Education$1170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 16 | $43,548 |
| Chiesi USA, Inc. | 3 | $5,913 |
| AstraZeneca | 1 | $2,168 |
| Biogen | 2 | $117 |
| Alnylam Pharmaceuticals Inc. | 1 | $73 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few neuromuscular medicine providers in New Hampshireto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LyricaPregabalin | 15 | $7,136 |
| Mycophenolate Mofetil | 18 | $4,138 |
| Pyridostigmine Bromide | 41 | $4,086 |
| Gabapentin | 82 | $1,390 |
| Pregabalin | 43 | $1,230 |
| Duloxetine Hcl | 22 | $409 |
| Prednisone | 34 | $191 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 14 | $26 |
Paid to pharmacies, not to this prescriber.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.